This is a working overview of Melanotan II, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-03 and is reviewed periodically as new material appears.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Dissolves readily in aqueous buffer |
| Typical storage temperature | -20 °C or below | Protect from light and moisture |
| Typical analytical method | Reversed-phase HPLC and LC-MS | Purity estimate plus mass confirmation |
| Unit of measure | Milligram per vial | Content varies by vendor |
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Late 14th – early 15th century: Sparse references to individual Cossacks. Late 15th – early 16th century: Cossacks specialising in military professions, mostly serving as mercenary border guards of the Commonwealth, Muscovy, Crimea or the Ottoman Empire, and living in settlements known as a sich. Last quarter of the 16th century – first half of the 17th century: Formation of the Cossacks as a separate social status with the establishment of the Cossack Registry and the recognition of the Zaporozhian Host. In English, Cossack is first attested in 1590.
== Non-enzymatic cofactors == The term is used in other areas of biology to refer more broadly to non-protein (or even protein) molecules that either activate, inhibit, or are required for the protein to function. For example, ligands such as hormones that bind to and activate receptor proteins are termed cofactors or coactivators, whereas molecules that inhibit receptor proteins are termed corepressors. One such example is the G protein-coupled receptor family of receptors, which are frequently found in sensory neurons. Ligand binding to the receptors activates the G protein, which then activates an enzyme to activate the effector. In order to avoid confusion, it has been suggested that such proteins that have ligand-binding mediated activation or repression be referred to as coregulators.
Cyanogen bromide is the inorganic compound with the formula BrCN. It is a colorless solid that is widely used to modify biopolymers, fragment proteins and peptides (cuts the C-terminus of methionine), and synthesize other compounds. The compound is classified as a pseudohalogen.
=== Australia === Nando's has been in continuous operation within Australia since 1990, when the first restaurant opened in Tuart Hill in Western Australia. As of August 2021, there were 155 restaurants in Australia; 63 in Victoria, 36 in Western Australia, 30 in Queensland, 16 in New South Wales, four in South Australia, two in the Northern Territory, three in Tasmania and two in the Australian Capital Territory. Per city, there are 59 in Melbourne, 34 in Perth, 20 in Brisbane, 15 in Sydney, four each in Adelaide and the Gold Coast, three in Ipswich, two each in Hobart, Canberra and Darwin and one each in Ballarat, Bunbury, Geelong, Kalgoorlie, Launceston, Newcastle, Rockhampton, Shepparton, the Sunshine Coast, Townsville and Traralgon. There have been various public battles between the parent company and its Australian franchisees.
Sources: en.wikipedia.org
Lucy Letby (born 4 January 1990) is a British former NHS neonatal nurse convicted of murdering seven babies and attempting to murder seven others at the Countess of Chester Hospital in Chester between June 2015 and June 2016. She was investigated after an unusual cluster of deaths in the hospital's neonatal unit. Charged in November 2020 with seven counts of murder and fifteen counts of attempted murder relating to seventeen babies, Letby was prosecuted on the basis of her presence at many of the incidents, two abnormal blood test results and skin discolouration interpreted as signs of insulin poisoning and air embolism, inconsistencies in medical records, her removal of nursing handover sheets from the hospital, and handwritten notes interpreted by the prosecution as a confession. In August 2023, she was found guilty on seven counts each of murder and attempted murder, and acquitted on two counts of attempted murder. The jury was unable to reach verdicts on six further counts. She received fourteen whole life orders, meaning life imprisonment without the possibility of parole. One of the unresolved attempted murder charges was retried in July 2024, resulting in a fifteenth whole life order. The senior management of the Countess of Chester Hospital was criticised for failing to act on clinicians' concerns, prompting the British government to commission an independent inquiry. Cheshire Police examined extra cases, resulting in three arrests related to corporate manslaughter. Two applications for permission to appeal have been refused by the Court of Appeal.
Vasopressin is released into the brain in a circadian rhythm by neurons of the suprachiasmatic nucleus. Vasopressin released from posterior pituitary is associated with nausea. Recent evidence suggests that vasopressin may have analgesic effects. The analgesia effects of vasopressin were found to be dependent on both stress and sex.
=== Antagonists and inverse agonists === Non-selective Agouti-related peptide Agouti signalling peptide MC2-selective Atumelnant (CRN04894) MC4-selective HS-014 HS-024 MCL-0042 MCL-0129 MPB-10 SHU-9119 (agonist at MC1 and MC5, antagonist at MC3 and MC4)
Sources: en.wikipedia.org
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.
Reversed-phase liquid chromatography estimates purity, and mass spectrometry confirms molecular mass. Together they distinguish the intended peptide from truncated or modified forms. Sequence-level confirmation may use tandem mass spectrometry or amino acid analysis.
Because it is not made under pharmaceutical standards, purity and content can vary between vendors and batches. Independent testing has documented labeling discrepancies. A certificate of analysis from an accredited laboratory offers more assurance than a vendor's own claim.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.